<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/botox-cosmetic-onabotulinumtoxina-introduces-the-confidence-collectives-entrepreneur-class-of-2026-302808548.html">BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective&#39;s Entrepreneur Class of 2026</a>
    </div>

      <div class="me-0 me-md-5">
        250 Women Entrepreneurs Have Been Selected to Join a Multi-Week Skill-Building, Mentorship, and Networking Program BOTOX® Cosmetic Will Award 20 Participants With $20,000 Grants Each to Help Take Their Business Dreams to the Next Level IRVINE, Calif., June 24, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the 2026 cohort of entrepreneurs selected to p...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/allergan-aesthetics-receives-approval-for-boey-trenibotulinumtoxine-in-canada-the-first-and-only-rapid-onset-short-duration-neurotoxin-for-the-temporary-improvement-of-frown-lines-in-adult-patients-302807467.html">Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients</a>
    </div>

      <div class="me-0 me-md-5">
        Canada is the first country to approve a new botulinum neurotoxin serotype for aesthetic use Boey ® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved for the temporary improvement in the appearance of glabellar lines Boey® offers a differentiated treatment option for many people who are curious about facial injectables Results may be seen as early as ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/abbvie-announces-european-commission-approval-of-maviret-glecaprevirpibrentasvir-for-people-with-acute-hepatitis-c-virus-infection-302806984.html">AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection</a>
    </div>

      <div class="me-0 me-md-5">
        MAVIRET ® (glecaprevir/pibrentasvir) is now approved in the European Union for the treatment of acute hepatitis C virus (HCV) infection with compensated liver disease (with or without cirrhosis) in adults and children aged 3 years and older. The approval gives clinicians an option to initiate treatment as soon as acute infection is confirmed, aiming to reduce delays in care and lower the risk o...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/abbvie-announces-european-commission-approval-of-skyrizi-risankizumab-for-the-treatment-of-pediatric-patients-with-moderate-to-severe-plaque-psoriasis-302807045.html">AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis</a>
    </div>

      <div class="me-0 me-md-5">
        SKYRIZI ® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis 1 Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg 1 Nearly a third of people living with psoriasis develop sy...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Proactive Investors</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.proactiveinvestors.com/companies/news/1094268?SNAPI">AbbVie to acquire Apogee Therapeutics in $10.9B deal</a>
    </div>

      <div class="me-0 me-md-5">
        Abbvie Inc (NYSE:ABBV) announced that it will acquire Apogee Therapeutics (NASDAQ:APGE) in an all-cash transaction valued at approximately $10.9 billion, adding a pipeline of clinical-stage therapies for inflammatory and immunological diseases, including atopic dermatitis and asthma. Under the terms of the definitive agreement announced Sunday, AbbVie will acquire all outstanding Apogee shares ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Investors Business Daily</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.investors.com/news/technology/abbvie-apogee-therapeutics-acquisition-apogee-stock/">AbbVie Goes On The Offensive With $10.9 Billion Takeover</a>
    </div>

      <div class="me-0 me-md-5">
        AbbVie announced Monday a $10.9 billion plan to acquire immunology-focused Apogee Therapeutics, sending Apogee stock flying.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Investopedia</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.investopedia.com/5-things-to-know-before-the-stock-market-opens-june-22-2026-12003658">5 Things to Know Before the Stock Market Opens</a>
    </div>

      <div class="me-0 me-md-5">
        Stocks are having a quiet morning Monday as investors come off a long holiday weekend with a close eye on peace talks between the U.S. and Iran; a second day of negotiations in Switzerland has reportedly concluded after renewed threats against Iran from President Trump and continued attacks in Lebanon by Israel made for an eventful first day of talks; earnings from FedEx and Micron are on tap t...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/AbbVie-US00287Y1091">AbbVie</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">WSJ</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.wsj.com/business/deals/abbvie-to-buy-apogee-therapeutics-for-10-9-billion-in-cash-80102ca0">AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash</a>
    </div>

      <div class="me-0 me-md-5">
        AbbVie has agreed to buy Apogee Therapeutics for about $10.9 billion in cash in a deal that bolsters the biopharmaceutical company&#39;s immunology and inflammation portfolio.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/AbbVie-US00287Y1091/load_more?page=7">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>